In this video, Dr. Ronald Goldenberg, an endocrinologist at LMC Diabetes and Endocrinology, discusses the evolving landscape of first-line therapy for type 2 diabetes. He reviews the historical role of metformin, the impact of landmark trials such as the UK Prospective Diabetes Study and explores the potential benefits of newer agents like SGLT2 inhibitors and GLP-1 receptor agonists, emphasizing individualized treatment approaches based on patient profiles and comorbidities.
Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment?
CAN-eng
$0
free
Unaccredited
10 min
Diabetes,Medication Management
0 Credits
Course Description
Course Details
Expiry Date: 2025-10-01
Professions: Physician,Nursing,Pharmacy,Allied Health,Medical Resident,Student,Specialist
Faculty
- Ronald Goldenberg, MD, FRCPC, FACE
Accreditation
Learning Objectives
After viewing this expert brief, participants will be better able to:
- Understand the historical role of metformin in type 2 diabetes management and the evidence supporting its use
- Evaluate the cardio-renal benefits and glucose-lowering effects of newer agents, such as SGLT2 inhibitors and GLP-1 receptor agonists
- Analyze the evolving guidelines and recommendations for individualizing first-line therapy based on patient comorbidities and risk factors
